Article
Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders.
BMC pediatrics - 2 Jul 2025
Xin Yingying, Gao Liuliu, Li Sichan, Wang Jun, Chen Chen, Tuo Yali, Nie Gang, Li Ruizhen, Sun Dan, Fu Yongli, Wang Yang, Liu Zhisheng
Abstract excerpt
BACKGROUND: Aripiprazole (ARI) is the first-line treatment for tic disorders (TD). Cytochrome P450(CYP)2D6 (CYP2D6) and ATP-binding cassette, sub-family B, member 1 (ABCB1) transporter are involved in the metabolism of ARI. However, whether CYP2D6 and ABCB1 genetic polymorphisms influence clinical efficacy and pharmacokinetics of ARI remains unclear. METHODS: CYP2D6 and ABCB1 genotyping were performed....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.